Background: A variety of therapeutic options have been reported for cutaneous lupus erythematosus (CLE); one of these is dapsone. However, no high priority has been given to this drug. Objective: To determine whether dapsone is an effective and safe treatment alternative in patients with LE. Methods: We reviewed the literature and analyzed retrospectively 34 CLE patients who were treated with dapsone as monotherapy or combined with antimalarials. We assessed the course of the disease under treatment, response, concomitant treatment and side effects. Results: Six patients went into remission, 14 patients improved, and in 6 patients disease remained constant during the observation period. Dapsone was discontinued in 9 patients: in 4 due to reversible side effects and in 5 patients due to poor efficacy. Conclusion: Our data confirm that dapsone with/without antimalarials is effective in more than 50% of patients with CLE and could be used as second-line therapy for CLE.

Keywords:
Dapsone, Retrospective study, Side effects, Chloroquine-hydroxychloroquine combination therapy, Systemic lupus erythematosus, Cutaneous lupus erythematosus, Antimalarials
1.
Kuhn A, Ruland V, Bonsmann G: Hautmanifestationen des Lupus erythematodes. Z Rheumatol 2011;70:213-227.
2.
Okon LG, Werth VP: Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol 2013;27:391-404.
3.
Kuhn A, Ruland V, Bonsmann G: Cutaneous lupus erythematosus: update of therapeutic options. J Am Acad Dermatol 2011;65:195-213.
4.
Winkelmann RR, Kim GK, Del Rosso JQ: Treatment of cutaneous lupus erythematosus: review and assessment of treatment benefits based on Oxford Centre for Evidence-Based Medicine criteria. J Clin Aesthet Dermatol 2013;6:27-38.
5.
Wozel G, Blasum C: Dapsone in dermatology and beyond. Arch Dermatol Res 2014;306:103-124.
6.
Working Group of the Scientific Medical Societies. Guideline of the German Dermatology Society: Kutaner Lupus Erythematodes. 2008, http://www.awmf.org/uploads/tx_szleitlinien/013-060_abgelaufen.pdf (accessed January 18, 2015).
7.
Bacman D, Kuhn A, Ruzicka T: Dapsone and retinoids; in Bacman D, Kuhn A, Ruzicka T (eds): Cutaneous Lupus Erythematosus. Berlin, Springer, 2004, pp 373-390.
8.
Ludgate MW, Greig DE: Bullous systemic lupus erythematosus responding to dapsone. Australas J Dermatol 2008;49:91-93.
9.
Maibach HI, Gorouhi F (eds): Evidence Based Dermatology, ed 2. Shelton, People's Medical Publishing House, 2011.
10.
Lindskov R, Reymann F: Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986;172:214-217.
11.
Coburn PR, Shuster S: Dapsone and discoid lupus erythematosus. Br J Dermatol 1982;106:105-106.
12.
Yamada Y, Dekio S, Jidoi J, Ozasa S: Lupus erythematosus profundus - report of a case treated with dapsone. J Dermatol 1989;16:379-382.
13.
Ruzicka T, Goerz G: Dapsone in the treatment of lupus erythematosus. Br J Dermatol 1981;104:53-56.
14.
Holtman JH, Neustadt DH, Klein J, Callen JP: Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol 1990;17:1222-1225.
15.
McCormack LS, Elgart ML, Turner ML: Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 1984;11:397-401.
16.
Tsutsui K, Imai T, Hatta N, Sakai H, Takata M, Takehara K: Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. J Am Acad Dermatol 1996;35:313-315.
17.
Fenton DA, Black MM: Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1986;11:102-103.
18.
Böhm I, Bruns A, Schupp G, Bauer R: ANCA-positiver Lupus erythematodes profundus. Erfolgreiche Therapie mit niedrig dosiertem Dapson. Hautarzt 1998;49:403-407.
19.
Ujiie H, Shimizu T, Ito M, Arita K, Shimizu H: Lupus erythematosus profundus successfully treated with dapsone: review of the literature. Arch Dermatol 2006;142:399-401.
20.
Pinto-Almeida T, Sanches M, Alves R, Selores M: Vesico-bullous subacute cutaneous lupus erythematosus - an uncommon entity successfully treated with dapsone and hydroxychloroquine. Dermatol Online J 2012;18:13.
21.
Nasongkhla P, Pratchyapruit W, Tagami H: Bullous systemic lupus erythematosus induced by UVB: report a case. J Med Assoc Thai 2012;95:969-973.
22.
Yung A, Oakley A: Bullous systemic lupus erythematosus. Australas J Dermatol 2000;41:234-237.
23.
Hall RP, Lawley TJ, Smith HR, Katz SI: Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 1982;97:165-170.
24.
Grover C, Khurana A, Sharma S, Singal A: Bullous systemic lupus erythematosus. Indian J Dermatol 2013;58:492.
25.
Liu K, Shen J, Yang C, Chen YJ: Bullous systemic lupus erythematosus in a child responding to dapsone. Pediatr Dermatol 2014;31:104-106.
26.
Tay YK, Wong SN, Tan T: Bullous systemic lupus erythematosus - a case report and review. Ann Acad Med Singapore 1995;24:879-882.
27.
Neri R, Mosca M, Bernacchi E, Bombardieri S: A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with dapsone. Lupus 1999;8:240-243.
28.
Seo JY, Byun H, Cho KH, Lee EB: Methimazole-induced bullous systemic lupus erythematosus: a case report. J Korean Med Sci 2012;27:818-821.
29.
Chan Y, Mok CC, Tang WY: Erythema elevatum diutinum in systemic lupus erythematosus. Rheumatol Int 2011;31:259-262.
30.
Lorenz M, Wozel G, Schmitt J: Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 2012;92:194-199.
31.
Zhu YI, Stiller MJ: Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001;45:420-434.
32.
Wozel VE: Innovative use of dapsone. Dermatol Clin 2010;28:599-610.
33.
Pfeiffer C, Wozel G: Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2003;48:308-309.
34.
Deps P, Guerra P, Nasser S, Simon M: Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. Lepr Rev 2012;83:305-307.
35.
Ziemer M, Milkova L, Kunz M: Lupus erythematosus. II. Clinical picture, diagnosis and treatment. J Dtsch Dermatol Ges 2014;12:285-301; quiz 302.
36.
Chang AY, Werth VP: Treatment of cutaneous lupus. Curr Rheumatol Rep 2011;13:300-307.
37.
Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H: Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992;127:513-518.
38.
Ezra N, Jorizzo J: Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. Clin Exp Dermatol 2012;37:327-334.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.